Finch Therapeutics Funding: $184M Raised, Series C (2019)
Finch Therapeutics is based in Somerville. It has raised $184M in total funding. Latest round: Series C.
Finch Therapeutics funding overview
Finch Therapeutics is based in Somerville. Finch Therapeutics has raised $184M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series C announced in August 2019. The round record for Finch Therapeutics runs through 2019; nothing later has been disclosed. Investors on record include OCV Partners, Susquehanna International Group (SIG), Symbiosis LLC, Trans-Pacific Technology Fund, Avenir Growth Capital, Morgan Noble and 2 others. 8 distinct backers are named across the disclosed rounds.
Finch Therapeutics at a glance
Total raised
$184M
Latest round
Series C
Latest round date
August 2019
Headquarters
Somerville
Notable investors
OCV Partners, Susquehanna International Group (SIG), Symbiosis LLC, Trans-Pacific Technology Fund, Avenir Growth Capital, Morgan Noble, Shumway Capital, Willett Advisors
Frequently asked about Finch Therapeutics funding
How much has Finch Therapeutics raised?
Finch Therapeutics has raised $184M in total disclosed funding across the rounds on record.
Who has invested in Finch Therapeutics?
OCV Partners, Susquehanna International Group (SIG), Symbiosis LLC, Trans-Pacific Technology Fund, Avenir Growth Capital, Morgan Noble are named among the investors backing Finch Therapeutics.
What was the latest Finch Therapeutics funding round?
The most recent disclosed round is a Series C, announced in August 2019.
Where is Finch Therapeutics based?
Finch Therapeutics is based in Somerville.
When did Finch Therapeutics last raise?
The last disclosed Finch Therapeutics round closed in August 2019 at Series C.
Every Finch Therapeutics figure above comes from filings and announced rounds in the StartupFundraising company database and is revised as new rounds are recorded. The lists below compare companies in Somerville at a similar stage.
